+353-1-416-8900REST OF WORLD
+44-20-3973-8888REST OF WORLD
1-917-300-0470EAST COAST U.S
1-800-526-8630U.S. (TOLL FREE)
New

Veracyte Inc (VCYT) - Product Pipeline Analysis, 2026 Update

  • PDF Icon

    Company Profile

  • 58 Pages
  • August 2026
  • GlobalData
  • Veracyte Inc
  • ID: 5740084
Veracyte Inc (Veracyte) is a molecular diagnostics company that specializes in genomic testing for cancer diagnosis and treatment. The company’s products include Afirma genomic sequencing classifier for thyroid cancer, Decipher prostate genomic classifier targets prostate cancer; the prosigna breast cancer assay, which treats breast cancer; Decipher bladder genomic classifier targets bladder cancer; Percepta nasal swab test treats lung cancer; and Lymphmark targets diffuse large B-cell lymphoma. Its MRD technology platform delivers high-performing cancer tests by broad genomic and clinical data, deep bioinformatic and AI capabilities, and a powerful evidence-generation engine. The company operates in the US, the Netherlands, France and Israel. Veracyte is headquartered in San Francisco, California, the US.

This report is a source for data, analysis, and actionable intelligence on the company’s portfolio of pipeline products. The report provides key information about the company, its major products and brands.

The report enhances decision making capabilities and help to create effective counter strategies to gain competitive advantage.

Scope:

  • The report reviews detailed company profile with information on business description, key company facts, major products and services, key competitors, key employees, locations and subsidiaries and recent developments
  • The report analyzes all pipeline products in development for the company Veracyte Inc
  • The report provides pipeline analysis on all pipeline products of the company (by equipment type, by indication, by development stage, and by trial status)
  • The report covers detailed information on each pipeline product with information on pipeline territory, stage of development, device class, regulatory path, indication(s), application(s) and estimated launch date
  • The report provides detailed description of products in development, technical specification and functions
  • The report also covers ongoing clinical trials (wherever applicable) with information on trial name, trial objective, sponsor, trial design, trial status and phase, estimated start and end date.

Reasons to Buy:

  • Develop business strategies by understanding the trends and developments driving the medical devices pipeline and technology landscape
  • Design and develop your product development, marketing and sales strategies by understanding the competitor portfolio
  • To formulate effective Research & Development strategies
  • Develop market-entry and market expansion strategies
  • Exploit in-licensing and out-licensing opportunities by identifying products, most likely to ensure a robust return
  • Plan mergers and acquisitions effectively by identifying key players of the most promising pipeline
  • Identify emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage
  • Develop competition strategies by identifying the status and likely launch of the competitors’ pipeline products through review of the clinical trials, stage and of development, etc
  • Identify, understand and capitalize the next high-value products that your competitor would add in its portfolio
Note: Some sections may be missing if data is unavailable for the company